Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), Churchill Hospital, Oxford OX3 7LE

Daniel Brandhorst

Dr.oec.troph., Ph.D

Senior Researcher

My research interest is to reduce hypoxia-induced damage in human islets of Langerhans during pancreas procurement, after isolation and subsequent to transplantation.

During the last years we identified perfluorohexyloctane as an efficient oxygen carrier for human pancreas preservation. This substance is characterised by increased lipophilicity and lower gravity compared to already established compounds and recently obtained approval for clinical use. We are currently aiming to develop an emulsion that combines the characteristics of both hyperoxygen carriers and organ preservation solutions.

In contrast to whole pancreases isolated islets can easily be treated during cell culture to increase their resistance toward hypoxia-induced damage prior to and after transplantation into recipients. Currently, we investigate whether islet susceptiblity toward hypoxia can be reduced by inducing intrinsic mechanisms for stress resistance or by using potentially protective substances.